1. |
Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era——a population-based study in western Sweden [J]. Cancer, 2005; 103(4)∶821.
|
2. |
D’Amato G, Steinert DM, McAuliffe JC, et al. Update on the biology and therapy of gastrointestinal stromal tumors [J]. Cancer Control, 2005; 12(1)∶44.
|
3. |
Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis [J]. Am J Surg Pathol, 1983; 7(6)∶507.
|
4. |
Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract [J]. Histol Histopathol, 2000; 15(4)∶1293.
|
5. |
Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO [J]. Ann Oncol, 2005; 16(4)∶566.
|
6. |
Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop [J]. Hum Pathol, 2001; 32(6)∶578.
|
7. |
刘勇, 易瑛, 曾涛. 胃肠间质瘤的诊治分析(附21例报告) [J]. 中国普外基础与临床杂志, 2006; 13(1)∶100.
|
8. |
Benjamin RS, Rankin C, Fletcher C, et al. Phase Ⅲ dose-randomized study of imatini Mesylate(STI571)for GIST: intergroup S0033 early results(abstract 3271) [J]. Proc Am Soc Clin Oncol, 2003; 22(1)∶814.
|
9. |
Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor [J]. N Engl J Med, 2001; 344(14)∶1052.
|
10. |
赵成艳, 马荣, 王忠利, 等.非霍奇金淋巴瘤患者T细胞亚群、NK细胞检测的临床意义 [J]. 中国免疫学杂志, 2006; 22(2)∶180.
|
11. |
Nishioka Y, Wen H, Mitani K, et al. Differential effects of IL-12 on the generation of alloreactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide [J]. J Leukoc Biol, 2003; 73(5)∶621.
|
12. |
皋岚湘, 丁华野, 邓永江, 等. 乳腺癌组织Bcl-2、P53和c-erbB2 蛋白表达和相互关系及意义 [J]. 中华病理学杂志, 1996; 25(3)∶165.
|